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1. Introduction 
Cerebral venous thrombosis is a relatively rare, however life-threatening condition. Current 
studies show that around 10% of the patients die. Earlier works proved that most of the 
thromboses originated secondarily, as a consequence of local or systemic infection, more 
than 30% of the cases were considered to be idiopathic. More recent studies also mention 
other risk factors, which may contribute to the onset of thrombosis. These include 
thrombophilic states or use of oral contraceptives. A number of hypercoagulation states or 
thrombophilic conditions, which contribute to the onset of thromboembolic disease, have 
been discovered and described in the recent years. 
Thrombophilia is a congenital or acquired disorder of the haemostatic mechanism, 
characterized with an increased tendency towards blood clotting and thrombotization. Typical 
manifestations of the condition include frequent occurrence of lower extremities thromboses in 
young age, with frequent recurrence, or localization in unusual places. Congenital forms of the 
disorder are characterized with family occurrence. The most frequent conditions associated 
with congenital form of the disease are mutation of genes coding VLeiden factor (Leiden 
mutation), prothrombin G20210A, hyperhomocysteinemia and furthermore also autosomal 
inheritance of antithrombin III (AT III), protein C and protein S deficit. 
The point mutation of the factor V gene usually occurs in the place of protein C binding, 
which results in its cleavage and inactivation. The changes are associated with substitution 
of guanine with adenine at the 1691st nucleotide of the factor V, this substitution results in 
further substitution of glutamine with arginine on the 506th position of the factor V chain 
(FV Q506). The mutation is also known as “Leiden mutation”, based on the place of its 
discovery (Leiden, Holland). Substitution of amino acids in the factor V chain causes 
resistance against the activated protein C, resulting in a higher tendency towards 
thrombosis. The mutation is considered to be autosomal dominant hereditary. It affects 5-9% 
of the European population. The mechanism of resistance against the activated protein C 
(APC resistance) was first described by Dahlbäck in 1993 in Sweden. 
Another possible predisposition factor of venous thrombosis is a mutation of gene for 
prothrombin - G20210A variant. It is present in about 2% of the population. The mutation 
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causes an increase of the prothrombin level and contributes to elevation of the risk of 
thrombosis up to threefold level.  
Deficit of the antithrombin III is a disorder with most prothrombotic effects. The risk of 
developing a thromboembolic disease during life is 70-80% in carriers in the heterozygous 
form (homozygous carriers suffer from a lethal thromboembolic event usually already 
during childhood). AT III is a polypeptide synthetized in hepatocytes with an increased 
half-time (65 hours). Apart from its effect on thrombin, AT III is also able to activate factors 
Xa, IXa, VIIa and plasmin. The activation of antithrombin III is increased up to 40 000 times 
with heparin binding. The deficit of AT III is caused by numerous point mutations, deletion 
and insertion, and the inheritance is mostly autosomally dominant.  
Homocysteine is contained in plasma at concentrations of 5 – 16 mol/l. Congenital 
hyperhomocysteinemia may be caused by a number of enzymatic defects. Clinical 
manifestations may be strengthened with a deficit of B6 and B12 vitamins, folic acid or 
during a treatment with methotrexate. Thrombophilia caused by hyperfibrinogenemia and 
dysfibrinogenemia is observed significantly less frequently. 
Large population studies aimed at the relations between hormonal contraceptives and deep 
vein thrombosis have been performed. The increased risk was described mainly in patients 
using third-generation gestagens. Moreover, the identified risk of thrombosis in patients 
using hormonal contraceptives with thrombophilia is higher than what would correspond 
with a simple addition of risks. This finding confirms the theory that the procoagulation 
mechanisms are mutually strengthened in these women. 
The problems of cerebral venous thrombosis in women in fertile age, who are the users of 
hormonal contraceptives have been studied in several trials including only a small number 
of patients. The results are in many cases misleading and inconsistent. 
The aim of our study was to analyse cases of CVT in relation to sex, age, use of hormonal 
contraceptives and thrombophilic states, in correlation with CT, MRI and DSA findings and 
with clinical neurological findings. 
2. Clinical study 
We present a set of eight cases of women with a diagnosed cerebral venous thrombosis. The 
age scope of the group was 18.7 – 39.3 years of age, with mean of 28.1 years. The patients 
were hospitalized between April 2004 and October 2005. All patients were referred to CT / 
MRI and DSA venography examinations. Five of the women were treated with a therapeutic 
dose of low-molecular heparins (LMWH) only, with a transfer to warfarin treatment, other 
three patients underwent an interventional treatment with local thrombolysis with 
Actilyse® (rt-PA), following an ineffective LMWH application. 
We have evaluated all medical records of the patients, the patients were examined 
physically and we have taken a detailed history record. Seven patients were using third-
generation hormonal contraceptives with gestagens, one patient was using purely gestagen 
contraceptives, none of the patients smoked. 
3. Laboratory examinations 
All patients were referred for blood tests in order to define the presence of thrombophilic 
states. The blood samples were collected and tested prior to the onset of an anticoagulation 
treatment, and 3-6 months following a thrombotic event. 
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APC resistance was tested with the use of factor V deficient plasma (Coatest® APC resistance 
Chromogenix). The test presents almost 100% sensitivity and specificity in detection of factor V 
mutations (Leiden). Patients with APC ratio below 1.86 were tested with PCR analysis for the 
presence of FV:Q506  allele. We have also chromatogenously determined the levels of protein C, 
antithrombin III (AT III), prothrombin, heparin II cofactor and plasminogen. Protein S was 
determined immunologically, as a free form of protein S. 
In order to determine the complex mutations of FV 1691 G-A, prothrombin 20210 G-A and 
MTHFR 677 C-T, we used specific, polymerase chain reaction (MS PCR), according to the 
works of Austrian authors Endler et al. This method is a single-tube PCR technique based 
upon the use of allele-specific primers, differing mutually in 8-10 pairs of bases (bp). The 
subsequent amplification was carried out in accordance with the protocol, which was 
optimised for thermocycler Perkin Elmer 2400. Following the initial 10-minute denaturation 
at 95°C, 34 cycles follow, consisting of separation of DNA chains for 1 min at 95°C , 
annealing primers for 2 min at 56°C and DNA synthesis for 1 min at 72°C. After completion, 
final elongation was carried out for 7 min at 72°C, followed with cooling to 4°C. To separate 
the PCR products we used electrophoresis on Spreadex 400 gel (Elchrom Scientific), which 
enables separation of products up to 400 pb, with high resolution. The results were 
reviewed on UV review table at 254 nm, the photo documentation was obtained using a 
yellow filter with Mitsubishi camera enabling digital recording. 
3.1 Case Report of CVT – Application of local fibrinolysis in 24-year patient using HAK 
24-year-old female patient with a negative history, including pregnancy or 
thromboembolism used third-generation gestagen as oral contraceptives. The patient was 
admitted to Neurology ICU, suffering from a strong headache, localized retroaurically, 
lasting for the period of one week. During the previous two days, the pain was associated 
with vomiting. Neurological findings included IV-degree somnolence, apathy, dysarthria, 
nuchal rigidity with 12 points on the GCS (Glasgow Coma Scale) on admission. A CT 
examination and conventional DSA were carried out in the evening. Angiography showed a 
partial thrombotic closure of the superior sagittal sinus and complete closure of right-hand 
lateral and sigmoid sinus, Galen’s vein and direct sinus with stagnation of venous drainage 
in thalamus and basal ganglia. CT examination confirmed hypodensity in the right side of 
the thalamus and basal ganglia, oedema in right-hand temporal-occipital area and a minor 
haemorrhage in the area of right lateral and sigmoid sinus. 
Neurological examination  
The examination showed left-hand hemiparesis, divergent strabismus, bilateral miosis, 
nuchal rigidity and tachycardia 120/min. Oedema of the papillae was not present. 
Considering the progreding disorder of consciousness gradating into coma, the patient was 
intubated and left on artificial ventilation. Consequently, the patient was taken to 
Anaesthesiology-Resuscitation Department. We introduced anticoagulation treatment with 
dalteparine 1000 IU/hr and antibiotic therapy with amoxyciline with clavulanic acid 1,2 g/ 
8 hrs and ciprofloxacine 100 ml/12 hrs. The ventilation was maintained with FiO2 0,3, tidal 
volume (Vt) 550 ml and positive end-expiratory pressure (PEEP) of 5 cm H20. ECG was 
normal, without any ischemic signs, frequency 120/min. Magnetic resonance and magnetic 
resonance venography (MRV) confirmed vasogenic inflation, blood hypovolemia of the 
right mesencephalum, right thalamus and basal ganglia, as well as thrombosis of deep 
cerebral veins and venous sinuses. 
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Laboratory examination  
Creatinine 63,6 umol/l, glucose 6,1 mmol/l, coagulation: INR 1,41, fibrinogen 4,69 g/l, D 
dimers elevated 6-fold, protein C 45%, free protein S 56%, APC resistance negative- 4,791, 
AT III- 74%, factor II 76%, factor VIII – 112% (% of the standard). 
Despite the use of conventional anticoagulation treatment and anti-oedematous therapy 
according to the protocol, the serious brain stem symptoms progreded on the 5th day after 
admission, associated with a loss of vertical and horizontal oculocephalic reflexes. The patient 
was referred to interventional centre for endovascular treatment of cerebral venous 
thrombosis. After admission, a control DSA examination with three-dimensional venography 
(3D-XRV) was carried out, with reconstruction of the venous phase. We found an incomplete 
thrombotic closure of both venae cerebri internae, Galen’s vein and direct sinus, as well as a 
complete thrombosis of the right transversal and sigmoid sinuses. On the basis of this imaging 
examination, we decided to proceed with a local thrombolysis with rt-PA. 
Technique of the procedur  
5F Terumo loader (Radiofocus, Tokyo) was inserted into the common femoral vein for the 
purpose of a venous approach, and another 5F Terumo loader was inserted retrogradely into 
common femoral artery for angiography imaging of the right-side carotid basin. Control 
position digital subtraction angiography was carried out with the 4F Vertebral Aqua - Tempo 
catheter (Cordis - Endovascular, JJ, Miami, FL), with 3D-Xra reconstruction of the venous 
phase, with the outcome of a complete thrombolysis of the basal Rosenthal’s and Galen’s 
veins, sinus rectus, sinus transversus, sinus sigmoideus and right jugular vein (Fig. 1). The 
patient received unfractionated Heparin in the dose of 5000 U i.a. Another 4F Vertebral Aqua – 
Tempo catheter was inserted into the right v. jugularis interna, using the Terumo 035´/260cm 
loader (Radiofocus, Tokyo, Japan), and subsequently smoothly through the thrombus up to 
the area of confluens sinuum (Fig. 2). We have initiated local continuous thrombolysis on the 
5th day after admission, using the application of rtPA in the dose of 0,6mg/hr, with continuous 
application of UF Heparin in the dose of 700 IU/hr, to reach the therapeutic levels of 
anticoagulation therapy. Fibrinogen, aPTT, blood count and the count of thrombocytes were 
monitored in 6-hour intervals. The thrombolytic treatment lasted for a total of 48 hours. 
Control angiography with 3D-XRA venography performed on the 7th day confirmed 
recanalization of both cerebri internae, basal Rosenthal’s vein, Galen’s vein, sinus rectus, 
transversal and sigmoid sinuses, as well as v. jugularis interna, with a rapid drainage into 
cortical collectors. Thrombolytic therapy was terminated after the restoration of venous flow. 
Control CT examination excluded bleeding complications, and subsequent MRI examination 
confirmed regression of hyperaemia in the area of thalamus and right basal ganglia. 
During the following two days, the patient wakes from the comatose state, with further 
diminishing of clinical symptomatology in the following period. The NIHSS scale was scored 
at 4 points on the 7th day after the interventional procedure. During a follow-up check after 
one month, the patient is fully self-sufficient, with mRs – 0 points. The examination aimed at 
thrombophilic states verified heterozygous form of MTHFR: A/V 223 and homozygous form 
of PAI-I 4G/5G genotype mutation. The patient was introduced to anticoagulation treatment 
with warfarin, with periodical monthly INR check-ups. Subsequent neuro-psychological 
examination confirmed an excellent outcome: WAIS-R:IQ global test 141, verbal 128 and non-
verbal 146 points, with Wechsler memory quotient MQ l0l, pointing towards high intellectual 
functions. The examination further confirmed a high psychomotor speed, optimal verbal 
expression and memory functions at three months after the treatment. 
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A, B, DSA (day 1) closure of sinus transversus, vena magna cerebri  (Galen), vena cerebri interna and 
vena basalis Rosenthali. Drainage of cortical venous collectors preserved. 
C,D, T2- weighted images (day 4)- hyperaemia, or cerebral turgescence of right-hand side basal ganglia 
and the thalamus, with an image of signal hypersensitivity, imitating cerebral ischemia.  
E, MR venography – lateral image (day 4)- incomplete thrombosis of the sinus rectus, non-detectable 
flow in vena basalis  Rosenthali. 
F, Sagittal view on MR – venography – thrombosis of the right-hand side sinus transversus and 
sigmoideus and right vena jugularis interna. 
Fig. 1. DSA, MRI + MR- venography- „Time of Flight-TOF“  
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G, Sagittal view on DSA (day 5) – thrombosis of sinus transversus and sigmoid. 
H, 3D-Xra digital rotational angiography, partial thrombosis, sinus rectus – “double railing” image, 
thrombosis of vena basalis Rosenthali. Closure of right sinus transversus and sigmoid. 
I,4F-Vertebral Tempo Cordis JJ catheter inserted into right-hand sinus transversus, into the area of 
confluens sinuum, through a soft thrombus for introduction of local thrombolysis.  
J, Sagittal view - DSA (day 7) – 48 hours of local thrombolysis - recanalization of the right-hand side 
sinus transversus and sigmoid.  
Fig. 2. Interventional procedure + 3D-Xra control angiography and MRI after thrombolysis 
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K, L, 3D-Xra digital rotational angiography with a complete recanalization of sinus rectus, vena magna 
cerebri, vena basalis Rosenthali and venae cerebri internae. 
M, Control MRI – (1 month), with a minor venous infarction of pulvinar thalami on the right. 
Fig. 2. Continues.  
3.2 Case report – CVT with malignant course 
Thirty-three-year-old female patient with a negative history and negative allergic history, 
using third-generation hormonal contraceptives for a short period of one month was 
examined for a headache localised in the right-hand side occipital area, accompanied with 
repeated vomiting. After five days of cephalgias, the patient observed worsening of the 
visual acuity, namely in the right eye. The patient was admitted at Neurology department 
due to an epileptic seizure. The subsequent CT examination was described as negative. On 
admission, the patient complained about inappetence and overall sickness after using 
individual tablets of the contraceptive. On the 8th hospitalisation day, the patient suddenly 
lost consciousness, tonic stiffening of the limbs and jaw appeared, accompanied with 
sweating, and, having regained consciousness, the patient showed signs of overall 
confusion. Control CT examination was performed, with the image of squalid cortical areas 
and suspected subarachnoidal haemorrhage in the occipital area on the right, around 
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sinuses. Within further two hours, the patient lost consciousness, accompanied with 
meningeal symptomatology and left-side hemiparesis.  
The patient was referred for MRI examination, which revealed a massive cerebral venous 
thrombosis of all cerebral sinuses, with a closure of the deep vein system drainage in the 
diencephalic area and around basal ganglia (Fig. 3). After subsequently performed 
examinations, the patient was intubated in semi-comatose state and transferred to the 
interventional centre for an emergency endovascular procedure. 
Interventional procedure 
Under general anaesthesia, through a cannulation of right-hand side common femoral vein, 
we inserted 4F sheath Terumo and applied UF-Heparin 5000 U i.a.. Through the sheath we 
inserted 4F Vertebral Aqua - Tempo (Cordis - Endovascular, JJ, Miami, FL) diagnostic 
catheter and proceeded with diagnostic angiography of the cerebral arteries. The AG 
revealed a significantly delayed capillary filling, and venous drainage of both hemispheres, 
as well as a complete thrombosis of sinus sagitalis superior, sinus transversus and 
sigmoideus on the right side, a complete closure of deep venous drainage - v. basalis 
Rosenthali, v. cerebri internae, v. magna cerebri and sinus rectus. We inserted a second 5F 
Terumo loader into the common femoral vein, and through it a second diagnostic Vertebral 
catheter, on Terumo loader (Radiofocus, Tokyo, Japan) we penetrated into v. jugularis 
interna on the right, through foramen jugulare into sinus sigmoideus and transversus on the 
right, up to the confluens sinuum area. We initiated the application of local thrombolysis in 
the dose of 1mg rt-PA/hr per 24 hours. 
Therapy at the Anaesthesiology-Resuscitation Department 
Patient was left on controlled artificial lung ventilation, on antibiotics (amoxyciline with 
clavulanic acid i.v., at the dose of 1,2 g every 8 hours), parenteral infusion therapy with 
crystaloids, glucose, massive anti-oedematous therapy, continuous local thrombolysis.  
Laboratory examination 
Antithrombin III 88..67, Leukocytes 15,7; Erythrocytes 4,40; Haemoglobin 13,6, Haematocrit 
0,357; Thrombocytes 291; APTT 180 vt., Quick 19,4; INR l,62; Fibrinogen 3,0. 
Control CT on the following day  
Significant progression of the cerebral oedema, faded basal cisterns, clouded structures of 
the mesencephalon, smoothened gyrification, clouded structure of the right basal ganglia, 
medium line without deviation, faded lateral ventricles, high density in sinus sagitalis 
superior and sinus rectus with proven thrombosis. Conclusion – manifestation of a diffusive 
oedema, together with thrombosis of cerebral sinuses. 
Neurological examination 
Patient without attenuation, on artificial lung ventilation without any spontaneous activity, 
no reaction to painful stimuli, stem reflexes not manifested, generalized hypotonic state 
with C5-C8, L2-S2 areflexia. Conclusion: areactive coma, without manifestation of stem 
reflexes, corresponding to cerebral death. The patient dies on basal therapy after 11 days of 
hospitalization. 
Pathology-anatomic finding  
see Fig. 4. The image confirms extensive cerebral venous thrombosis, cerebral oedema, 
mainly in the area of brainstem, without manifestations of intracerebral haemorrhage. 
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N, T1WI-MRI - axial scan with the image of hyperintense signal of sinus transversus thrombosis on the 
right and hyperaemia, or vasogenic dilatation of the right temporal lobe.  
O,P T1WI-MRI axial scan with the image of hyperaemia, or vasogenic inflation of the right temporal 
lobe.  
Q, T1WI-MRI – image of “analogous delta sign” at the thrombosis at the area of division of the 
transversal sinus from confluens sinuum. 
R,S, TOF- MR venography with findings of sinus sagitalis superior, sinus transversus and sigmoideus 
thrombosis on the right, deep vein system - sinus rectus, v. magna cerebri, vv. cerebri internae, and v. 
basalis Rosenthali. 
Fig. 3. MRI examination and MR venography - (TOF) – sub-acute stage 
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T,U Thrombosis of sinus sagitalis superior as seen after opening of the sinus and removal of the hard 
meninges 
V Thrombosis of confluens sinuum and sinus rectus orifice, thrombosis of Labe collector on the right 
and cortical veins parietally on the left 
W Thrombosis of perimesenphalic veins with hyperaemia in the area of medulla oblongata 
Fig. 4. Pathology-anatomic finding 
4. Results 
We present eight cases of cerebral venous thrombosis in a group of young women (aged 
between 18.7 and 39.3 years, mean age 28.1 years), who were hospitalized between April 
2004 and October 2005. 
The most frequently observed manifestations of CVT (see Table 1) were headache (100%) 
and vertigo (87,5%). The most frequently detected objective findings were movement 
disorders – central hemiparesis or quadruparesis (75%), the same percentage applies to 
spasms, behavioural disorders, altered consciousness, sensoric disorders and aphasias 
(25%). CT and MRI examinations (see Table 3, 4) showed venous infarction or vasogenic 
inflation in 62.5% and presence of petechial haemorrhage in 25%. Digital subtraction 3D-XR 
venography most frequently confirmed a combination of occlusions of sinus transversus 
and sigmoideus (75%), sinus sagitalis superior (62,5%), cortical veins (62,5%) and deep 
venous system (50%). 
T U
V W
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The outcomes of the therapy were excellent in seven patients receiving the basic treatment. 
The treatment included administration of a combination of low weight molecular heparin in 
the treatment dose and subsequent coverage with warfarin. In three patients with 
insufficient effect of LMWH, we used local thrombolysis Actilyse ® (rt-PA). One of the 
women died, despite acute thrombolysis and complex therapy. The results of coagulation 
tests (see Table 6) showed the presence of several thrombophilic risk factors in all women in 
our group. Homozygous form of the MTHFR-C677T gene mutation was detected in three 
patients, two patients had a mutation of the gene for PAI-1 in homozygous form. A 
combination of both homozygous forms was detected in one patient, the combination was 
present in heterozygous forms in two patients. The tests further detected an elevated level of 
factor VIII in three patients, and five of the patients showed a deficit of protein S, always in 
combination with mutations of the gene responsible for MTHFR-C677T, three of these were 
present in homozygous form. 
5. Discussion 
The first clinical and pathological finding of cerebral venous thrombosis was described by 
Ribs in 1825 in a 45-year-old male patient with generalized malignant process. Without the 
possibility of angiography imaging, the diagnosis was determined on the basis of clinical 
findings – progreding headaches, oedema of the eye papilla, spasms, focal deficit, coma, and 
was most usually confirmed with pathology-anatomical findings of thrombosis in the area 
of dural sinuses, accompanied with haemorrhagic infarsation. In 2001, an important study 
“International Study of Cerebral Vein Thrombosis“ - ISCVT was published; the study 
prospectively monitored data of 624 patients with this diagnosis. (2)  
Deep vein system, including vv. cerebri internae, v. basalis Rosenthali, v. magna cerebri and 
sinus rectus, responsible for the drainage of diencephalon, basal ganglia and deep structures 
of the white matter of hemispheres, is usually affected in 10% of cerebral venous 
thromboses. More serious clinical cases, including hemipareses and quadrupareses are 
caused by compression of capsula interna, with unilateral of bilateral infliction of the 
thalami or basal ganglia, and can be diagnosed with non-invasive examinations, e.g. CT or 
MRI under the image of the oedema or haemorrhagic infarction. Limitations of venous 
outflow result in cerebral hyperaemia, mostly detected on MRI in patients with CVT (3,4,5). 
The diagnosis of CVT in our group of patients was confirmed with MRI imaging, MR 
venography and subsequently also with digital subtraction angiography. Liang et al. 
confirm the importance of three-dimensional imaging of magnetic resonance MP-RAGE 
venography, supported with the use of contrast, in the diagnostics of thromboses in the area 
of dural sinuses. This method was also very useful in our patient group. (6) As an 
alternative diagnostic procedure for CVT it is also possible to perform CT venography, 
together with the subtraction of bone structures “Mathed Mask Bone Elimination” (MMBE). 
(7) 3D-Xra-digital rotation venography provides an excellent alternative, with the possibility 
of imaging the speed and direction of the flow in a normal section of the venous system, as 
well as in partially thrombotized parts of dural sinuses and deep vein system. 
The treatment of patients with intracranial venous thrombosis depends on the timeliness of 
the clinical suspicion of CVT and subsequent confirmation of the diagnosis with imaging 
techniques. Purdon Martin and Sheehan (1941) were the first to recommend anticoagulation 
therapy for the treatment of CVT. The treatment with heparin is currently considered as a 
treatment of choice in patients with CVT. (2) However, the effect of heparin may be too 
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slow, especially in patients with rapidly progreding symptoms and involvement of most of 
the dural sinuses and deep venous system. This patient population should be referred for 
thrombolytic treatment, as the overall mortality of these patients reaches 10%. (8-11) Our 
current experiences also point towards the possibility of mechanical revascularization of the 
obstructed venous bed, using the techniques of rheolytic thrombectomy and mechanical 
disturbance of the thrombus with balloon catheters. (12,13) 
Thrombophilic states are commonly observed in 25-35% of patients with venous thrombosis. 
(14,15) Hormonal contraceptives are currently used by more than 100 million women. 
Shortly after their introduction in 1960s, an increased incidence of thrombotic vascular 
complications was observed (16-18), together with an interaction of hormonal contraceptives 
and haemocoagulation system. Increased activity of coagulation factors VII, VIII, X and 
fibrinogen is a common finding in most cases. (19) Martinelli et al. in their work define the 
risk of onset of cerebral venous thrombosis in users of hormonal contraceptives OR 6,1 95% 
CI (3,3 – 11,00). This potential risk may be further intensified by congenital haemostatic 
disorders. (20) 
Peroral contraceptives induce extensive changes in the fibrinolytic system. The levels of 
plasminogen and plazmin-alfa2-antiplazmin complex are elevated, also the activity of tissue 
activator of plasminogen (tPA) is increased, at the same time, the level of antigen inhibitor of 
the plasminogen-I activator (PAI-I) and the PAI-I activity are decreased, and many other 
changes occur. The fibrinolysis in the users of contraceptives is elevated, which is most 
probably caused by the response and compensation of the prothrombogenic state, caused by 
hormonal preparations. These changes are identical in preparations containing levonorgestrel, 
as well as third-generation gestagens. (21) Genetically conditioned thrombophilic states of the 
fibrinolytic system (PAI-I) increase the potential risk of the onset of thrombosis in HAK users. 
An increased activity and clustering of platelets was observed. (22) 
Hormonal contraceptives with third-generation gestagens are connected with an increased risk 
of venous thromboses, in comparison with previous generations of contraceptives. This risk is 
also present in women without V Leiden factor mutation or a positive family history. (23)   
6. Conclusion  
Our experience points towards the possibility of CVT onset in young women using 
hormonal contraceptives. This condition needs to be taken into account in cases of 
intracranial difficulties. CVT is most commonly manifested with headaches, vertigo and 
visual disorders. That is why the diagnosis should be considered when a sudden onset of 
such manifestations occurs in otherwise healthy young woman. The CT or MRI 
examinations should be directed towards the possibility of affection of the venous 
intracranial system. MRI and MR-venography or 3DX-RA venography significantly decrease 
the diagnostic process in patients with disorders of the deep venous cerebral system and a 
rapid development of symptoms. Direct endovascular thrombolysis, with the possibility of 
mechanical revascularization may dramatically improve the clinical course of patients with 
thrombosis of cerebral veins in patients with insufficient effect of anticoagulation therapy, 
associated with rapidly progreding disorders of consciousness. Thrombolytic therapy also 
decreases the occurrence of secondary complications following thrombolyses of cerebral 
veins, such as chronic intracranial hypertension with visual disorders or onset of arterio-
venous shunts. (24,25) Taking into account the incidence of these serious complications, we 
consider as essential, in compliance with recommendations of the Czech Society of 
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Gynaecology and Obstetrics JEP, prior to administration of HAK, to perform a detailed 
analysis of personal and family history, and in indicated cases also a detailed examination of 
the presence of thrombophilic states. The significance of individual thrombophile mutations is 
inconsistent. Absolute contraindications for HAK usage include deficit of the antithrombin III, 
protein C deficit, homozygous form of V Leiden factor and combination of other thrombophile 
mutations. Other thrombophile mutations present a relative contraindication only. Screening 
examination of women prior to administration of HAK is not indicated. (26) However, in our 
study group, although we performed a detailed retrospective analysis, the personal and family 
history were negative in all patients. Considering this fact there arises the question of a 
facultative possibility of thrombophile examination covered by the patient, based on the 
patient’s request, prior to administration of HAK. 
As a certain surprise we may mention the high incidence of homozygous form of C677T in 
out study group (37,5%), which may be in consistence with the findings of Martinelli et al., 
who proved the risk of CVT onset in users of hormonal contraceptives with 
hyperhomocysteinemia OR 19,5 95% CI (5,7 – 67,3). The levels of homocystein were not 
monitored in our patients. Other frequently observed findings included mutations of the 
plasminogen activator inhibitor gene  (PAI-1) and deficit of protein S, which may be also 
present in combinations strengthening the prothrombogenic effect. On the other hand, we 
did not observe an incidence of V Leiden factor in patients with CVT, however this factor is 
frequently mentioned in literature as a significant thrombophilic risk factor. 
7. Tables 
 
 1. 2. 3. 4. 5. 6. 7. 8. Mean 
Age 32.0 32.5 24.1 18.7 33.3 24.8 39.3 20.2 28.1 
Table 1. Age of patients included into the study 
 
Symptoms 1. 2. 3. 4. 5. 6. 7. 8. % 
Headache + + + + + + + + 100 
Vertigo  + + + + + + + 87.5 
Central hemiparesis 
and quadruparesis 
 + +  + + +  62,5 
Sight disorders    + +    25.0 
Sensitivity disorder  +    +   25.0 
Behavioural disorder       + + 25.0 
Aphasia  +     +  25.0 
Spasms     + +   25.0 
Coma   +  +    25.0 
Table 2. Subjective and objective manifestations on admission 
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CT/MR 1. 2. 3. 4. 5. 6. 7. 8. % 
Venous infarction, 
vasogenic inflation 
 + +  + + +  62,5 
Petechial 
haemorrhage 
    +  +  25,0 
 
Table 3. Parenchymatous lesions on CT/MRI 
 
 
 1. 2. 3. 4. 5. 6. 7. 8. % 
Sinus sagitalis 
superior 
+  + + +  +  62.5 
Sinus transversus,  
sigmoideus 
+  + + + + +  75,0 
Deep vein system   + + + +   50,0 
Cortical veins  + + + + +   62.5 
V.jugularis interna +  +     + 37.5 
Cerebellar veins      +   12.5 
 
Table 4. Occlusion of sinuses / cortical veins on DSA  3D- XR venography 
 
 
 1. 2. 3. 4. 5. 6. 7. 8. 
Contraceptiv
es 
+ + + + + + + + 
Treatment 
LMWH 
+ 
Wa 
LMWH 
+ 
Wa 
LKT 
+ 
LMWH 
+ 
Wa 
LKT 
+ 
LMWH 
+ 
Wa 
LKT 
+ 
LMWH
LMWH 
+ 
Wa 
LMWH 
+ 
Wa 
LMWH 
+ 
Wa 
Outcome 
Complete 
recovery 
Complete 
recovery
Complete 
recovery
Complete 
recovery
Patient 
died 
Complete 
recovery 
Complete 
recovery 
Complete 
recovery 
Smoking - - - - - - - - 
LMWH – Low Molecular Weight Heparin, Wa – warfarin, LKT -  local continuous thrombolysis 
 
Table 5. Therapy 
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 1. 2. 3. 4. 5. 6. 7. 8. 
Factor V  
Leiden 
- - - - - - - - 
MTHFR ++ ++ +- +- - ++ +- +- 
PAI-1 - - ++ - - ++ +- +- 
Factor VIII - - - + + + - - 
Hyperhomo-
cysteinemia 
+ - - - - - - - 
Protein C 
deficit 
+ - + - - - - - 
Protein S 
deficit 
+ + - + - + - + 
Antithrombi
n deficit 
- - + - - - - - 
Legend:- negative, +- heterozygous, ++ homozygous 
-MTHFR- methylentetrahydrofolate reductase, PAI- plasminogen activator inhibitor  
Table 6. Results of thrombophilic parameters 
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